| | 1454846-35-5 Basic information More.. |
| Product Name: | Lorlatinib | | Synonyms: | (10R)-7-Amino-12-fluoro-10,15,16,17-tetrahydro-2,10,16-trimethyl-15-oxo-2H-4,8-methenopyrazolo[4,3-h][2,5,11]benzoxadiazacyclotetradecine-3-carbonitrile;Lorlatinib,PF-06463922;PF-06463922, Lorlatinib;(R)-26-amino-55-fluoro-11,4,7-trimethyl-6-oxo-11H-3-oxa-7-aza-2(3,5)-pyridina-1(4,3)-pyrazola-5(1,2)-benzenacyclooctaphane-15-carbonitrile;Lorlatinib(PF0643922);High Purity API Lorlatinib;Anaplastic lymphoma kinase (ALK);Lorlatinib Powder | | CAS: | 1454846-35-5 | | MF: | C21H19FN6O2 | | MW: | 406.41 | | EINECS: | 813-704-5 | | Mol File: | 1454846-35-5.mol |  |
Use
Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase that promotes cell proliferation and blocks apoptosis. PF-06463922 is an ATP-competitive, selective inhibitor of ALK (Ki = < 0.07 nM) and c-Ros oncogene 1 (ROS1, Ki = 0.7 nM). It has strong activity against all known ALK and ROS1 mutants identified in patients, including the EML4-L1196M mutant of ALK (Ki = < 0.02 nM). PF-06463922 is orally available, displaying inhibition of ALK phosphorylation and antitumor efficacy in a xenograft model expressing EML4-L1196M ALK. It demonstrates efficient blood-brain barrier penetration, produces brain tumor regression in mice harboring EML4-ALK tumors, and increases overall survival.[Cayman Chemical]
- Lorlatinib
-
- US $0.00 / g
- 2024-08-05
- CAS:1454846-35-5
- Min. Order: 1g
- Purity: More Than 99%
- Supply Ability: 50kg/Month
- Lorlatinib
-
- US $0.00-0.00 / kg
- 2024-05-09
- CAS:1454846-35-5
- Min. Order: 1kg
- Purity: 99%，single impurity＜0.1
- Supply Ability: 1 ton
- Lorlatinib (PF-06463922)
-
- US $8.00-1.00 / KG
- 2024-03-29
- CAS:1454846-35-5
- Min. Order: 1KG
- Purity: 99%
- Supply Ability: g-kg-tons, free sample is available
|
|
1454846-35-5
Recommend Suppliers |
|